Skip to main content
Fig. 3 | Stem Cell Research & Therapy

Fig. 3

From: Catalpol promotes the osteogenic differentiation of bone marrow mesenchymal stem cells via the Wnt/β-catenin pathway

Fig. 3

The increased osteogenesis of BMSCs caused by catalpol treatment can be partially inhibited by a Wnt/β-catenin signalling inhibitor (DKK1). a–c The expression of osteogenic-specific and Wnt/β-catenin signalling-related genes and proteins were assessed by qRT-PCR (a) and WB (b, c) at day 7 of osteogenic differentiation. d–g Osteogenic differentiation was assessed by ALP staining (d), ALP activity assays (e) and Alizarin Red staining (f). Calcium deposition was determined by optical density analysis (g). The data were confirmed by three repeated tests. The data are presented as the means ± SD. CA, catalpol; β-catenin (T), total β-catenin; β-catenin (N), nuclear β-catenin. *P < 0.05 compared with the control group, #P < 0.05 compared with the catalpol treatment group

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512